CompletedNCT04109118
Support for Benzodiazepine Tapering During Opioid Treatment
About this title
Read the official source — NCT04109118Medication studyAges 18+United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- BostonSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: March 18, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 4
- Sponsor
- Boston Medical Center
- Sponsor type
- Hospital / academic medical center
- Study type
- Behavioral
- Intervention type
- Psychotherapy / behavioral intervention, Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT04109118
- Official title
Show the full official title
Distress Tolerance and Benzodiazepine Discontinuation in Opioid Agonist Therapy, Phase 2
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Boston
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Boston Medical Center, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including BZD discontinuation protocol.
Who was this study for?
Listed age limits: from 18 years.
